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INTRODUCTION 
Malaria is a major international public health problem. Malaria is 
seen in all the continents to a certain extent. At present it is endemic 
between the Tropics of Cancer and Capricorn. Malaria affects more 
than 500 million people and cause 2-3 million deaths each year. Despite 
its already enormous toll of suffering, deaths due to malaria are 
increasing as a consequence of drug resistance.1  
The global resurgence of malaria can be attributed to a variety of 
factors – insecticide resistance in the Anopheles mosquito, resistance of 
plasmodium falciparum to affordable first line antimalarials, deterioration 
of national control programs and increased movement of populations 
secondary to increase in international travel and tourism. 
Plasmodium falciparum is the most common cause of severe and 
life threatening malaria. It affects all age groups although the reported 
mortality varies considerably depending upon the age, immunity, clinical 
complications and access to appropriate treatment.2 
The mortality is higher in adults with severe falciparum malaria 
than in children with similar disease3 as evidenced by the fact that 
mortality amongst South East Asian adults with renal failure due to 
severe malaria is 45% while the mortality amongst Kenyan children with 
severe anemia is only 1%.4   Intensive care with facilities for ventilation 
and haemodialysis appears to reduce the mortality.5 
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The remedies to reverse the present situation are  
1) Better sanitation, engineering solutions to mosquito 
breeding 
2) Proper town and house planning 
3) Drug research along with the development of newer 
insecticides. 
4) Vaccine. 
The first two options are highly capital intensive and it is unlikely 
that the states endemic for malaria would be in a position to afford 
them. It is nearly a decade since any new antimalarial drug was 
developed. The low paying capacity of malaria victims makes drug 
development unattractive for pharmaceutical firms. Efforts are being 
made to remedy the situation by setting up organizations like the 
Medicines for Malaria Venture, Roll Back Malaria consortium. 
Among the South East Asian countries, India alone 
contributes more than 80% cases of malaria and plasmodium 
falciparum accounts for 35 – 40 % of cases.6  In an endemic area, 
apart from classical presentations of fever with chills and rigor of short 
duration, not uncommonly a completely different presentation may be 
encountered because of multisystem involvement in the disease 
process. 
 
 3
Therefore the study was carried out in acute falciparum malaria 
with objective of noting common presentations, atypical presentations if 
any, complications, hematological and biochemical abnormalities and 
their correlation with clinical severity and prognosis. 
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AIMS OF THE STUDY 
1) To find out common clinical presentations and also atypical 
presentation if any of acute plasmodium falciparum malaria. 
2) To assess life threatening complications of severe malaria. 
3) To collect a detailed hematological and biochemical profile 
in acute falciparum malaria with objective of noting its 
abnormalities and correlation if any with clinical severity 
and prognosis.                 
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REVIEW OF LITERATURE 
HISTORICAL BACKGROUND 
Malaria is probably one of the oldest diseases known to mankind. 
Man and malaria seem to have evolved together and it has been known 
to mankind for millennia. It was always part of ups and downs of 
nations, of wars and of upheavals. Mentions of this disease can be 
found in the ancient Chinese, Indian and Egyptian manuscripts. The 
disease supposedly had its origins in the jungles of Africa, where it is 
still very much rampant. 
In 1696, Morton presented the first detailed description of the 
clinical picture of malaria and its treatment with cinchona. In 1880, 
Laveran, a French physician first identified the causative agent for 
human malaria. In 1885, Golgi identified P.vivax and P.malariae. In 
1889, Sakharov and in 1890, Marchiafava and Celli identified 
P.falciparum. In 1894, Manson hypothesized that mosquitoes transmit 
malaria. 
In 1897, Sir Ronald Ross demonstrated the malarial oocysts in 
the gut tissue of female Anopheles mosquitoes proving the fact that 
Anopheles mosquito were the vectors for malaria. 
Chloroquine was synthesized and studied under the name of 
Resochin by the Germans as early as 1934. From them onwards lot of 
research into malarial parasite, host interactions, newer drugs and 
vaccine developments have come into effect. 
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GLOBAL TRENDS IN MALARIA 
• Malaria presents a public health paradox. Malaria prevails 
in Africa, South Asia and the Amazon and continually 
threatens the developed world. It thrives on poverty, 
population movement, and environmental disruption, all of 
which are in abundant supply in its current tropical 
homelands. Malaria is endemic in 91 countries with about 
40 % of world’s population at risk of acquiring the infection. 
Every year 300 million to 500 million people suffer from this 
disease1 (90% of them in sub-Saharan, Africa, two – thirds 
of remaining cases occur in six countries – India, Brazil, Sri 
Lanka, Vietnam, Colombia, and Solomon Islands.) 
• WHO forecasts a 16% growth in malaria cases annually 
• Malaria kills in 1 year what AIDS, killed in 15 years. If 5 
million have died of AIDS in 15 years, 50 million have died 
of malaria. 
• Malaria ranks third among the major infectious diseases in 
causing deaths – after pneumococcal acute respiratory 
infections and tuberculosis.  
• It accounts for 2.6% of the total disease burden of the 
world. It is responsible for the loss of more than 35 million 
disability – adjusted life years in the world. 
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• Estimated global annual cost (in 1995) for malaria: US$ 2 
billion (direct and indirect costs, including loss of labor). 
• Estimated world wide expenditure on malaria research: 
US$ 58 million, one thousandth of the US$ 56 billion spent 
globally on health research annually. 
STATUS OF MALARIA IN INDIA 
In India, with the implementation of Modified Plan of Operation in 
1977,   the upsurge of malaria cases dropped down from 6.74 million 
cases in 1976 to 2.1 million cases in 1984. Since then the 
epidemiological situation did not show any great improvement which 
seemed to have reached a plateau causing concern7.  
Since 1997, there is a declining trend in annual malaria incidence 
in the country. During the year 2003 about 1.65 million cases reported 
with 943 deaths. There were 0.7 million cases of P. falciparum malaria7. 
The disease is grossly under – reported.   
Malaria has been a serious problem in North – eastern states 
contributing 8.5 to 11 per cent of total malarial cases and 13 to 15 
percent of total malarial mortality in the country7 
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MALARIAL SITUATION IN INDIA7 
Year Cases in million Deaths API 
 Total cases P.falciparum   
1996 3.04 1.18 1010 3.4
8 
1997 2.66 1.04 879 2.8
6 
1998 2.22 1.03 664 2.4
4 
1999 2.28 1.14 1048 2.4
1 
2000 2.03 1.05 932 2.0
9 
2001 2.09 1.01 1005 2.0
6 
2002 1.84 0.89 973 1.8
0 
2003 1.64 0.70 943 1.6
2 
API-- Annual Parasitic Index 
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STATEWISE MALARIA SITUATION IN INDIA 2002 AND 20037 
2002 2003 STATE 
POSITIVE 
CASES 
DEATHS POSITIVE 
CASES 
DEATHS 
Andhra Pradesh 38053 0 35090 3
Arunachal Pradesh 46431 0 33366 0
Assam 89601 72 55375 38
Bihar 3683 2 2550 1
Chhattisgarh 235434 3 53093 0
Goa 16818 15 11370 1
Gujarat 82966 17 113372 34
Haryana 936 0 4336 0
Jharkhand 126589 31 112740 13
Karnataka 132584 33 99889 22
Kerala 3360 8 2380 4
Madhya Pradesh 108818 30 93780 22
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2002 2003 STATE 
POSITIVE 
CASES 
DEATHS POSITIVE 
CASES 
DEATHS 
Maharashtra 45568 43 62969 85
Manipur 1268 9 2589 17
Meghalaya 17918 41 16503 38
Mizoram 7859 35 7293 49
Nagaland 3945 0 3370 0
Orissa 473223 465 417276 333
Punjab 250 0 377 1
Rajasthan 68627 11 142738 66
Tamil Nadu  34523 0 43382 0
Tripura 13319 5 13577 9
Uttar Pradesh 90199 0 81853 0
West Bengal 194421 152 232846 207
Total 1842019 973 1647378 943
 
EPIDEMIOLOGY 
Like any other disease, natural transmission of malaria depends 
on the presence of and relationship between the three basic 
epidemiologic factors: the agent the host and the environment. While 
the malarial parasite is the agent of infection, the female anopheles 
mosquito is the agent of transmission.  
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There are about 400 species of anopheline mosquitoes 
throughout the world, approximately 80 can transmit malaria, 66 are 
considered natural vectors, and about 45 are important vectors.8 In 
India 9 species out of 45 anopheline species have been incriminated as 
malaria vectors7. 
The principal determinants of epidemiology of malaria are the 
number (density), the human – biting habits, and the longevity of the 
anopheles mosquito vectors.  More specifically, the transmission of 
malaria is directly proportional to the density of the vector, the square of 
the number of human bites per day per mosquito, and tenth power of 
the probability of the mosquito’s surviving for 1 day. Mosquito longevity 
is particularly important; it must survive for > 7 days.9 
MALARIAL TRANSMISSION CYCLE FROM MOSQUITO TO HUMAN 
The life cycle of the malarial parasite comprises of an 
endogenous asexual phase (schizogony) with multiplication in the 
human host and an exogenous sexual phase (sporogony) with 
multiplication in anopheles mosquitoes. 
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FIG.1 
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ASEXUAL PHASE IN THE HUMAN HOST 
TISSUE SCHIZOGONY ( PRE - ERYTHROCYTIC STAGE) 
This phase starts with the inoculation of the parasite into the 
human blood by bite of the female anopheles mosquito. Within half an 
hour the sporozoites reach the liver and invade the liver cells. The 
mechanism of targeting and invading the hepatocytes wih such rapidity 
is not yet clear. Within the liver cells, the sporozoite starts their 
intracellular asexual division. A single sporozoite eventually may 
produce 10,000 to 30,000 daughter merozoites.9 The swollen liver cell 
bursts, discharging motile merozoites into the blood stream. These then 
invade the RBCs and multiply 6 – 20 fold every 48 to 72 h9.  After entry 
into the blood stream merozoites rapidly invade erythrocytes and 
become trophozoites. 
ERYTHROCYTE  SCHIZOGONY 
Within the red cell, the parasite develops through the stages of 
rings, trophozoites, early schizonts, each mature schizont consisting of 
thousands of erythrocytic merozoites. These merozoites are released 
by the lysis of the red blood cells and they immediately invade 
uninfected cells. The intra erythrocytic cycle takes about 48 hours for P. 
falciparum9. A small proportion of the merozoites in the red blood cells 
undergo transformation into gametocytes – male and female. Mature 
gametocytes appear in the peripheral blood after 8 - 11 days of the 
primary attack in P. falciparum. 
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SEXUAL PHASE IN THE MOSQUITO 
SPOROGONY 
The gametocytes continue their development in the mosquito. 
The male and female gametes fuse and form into a zygote. This 
transforms into an ookinte9, penetrates the gut wall and becomes an 
oocyst. The oocyst divides asexually into numerous sporozoites which 
reach salivary gland.  
ERYTHROCYTE CHANGES IN MALARIA 
After invading an erythrocyte, the growing malarial parasite 
progressively consumes and degrades intracellular proteins, principally 
hemoglobin. Toxic heme is polymerized to biologically inert hemozoin or 
malarial pigment. It alters the RBC membrane and makes RBC more 
irregular in shape, more antigenic and less deformable9. In P. 
falciparum infections, membrane protuberances appear on the 
erythrocyte surface toward the end of the first 24 h of the asexual cycle. 
These knobs extrude adhesive protein (pfEMP1)9 that mediates 
attachment to receptors on venular and capillary endothelium – an 
event termed cytoadherence. ICAM-1 is probably the most important 
vascular receptor in the brain, chondroitin sulfate B in placenta, and CD 
36 in most other organs. 
At the same stage these infected RBCs may also adhere to 
uninfected RBCs to for rosettes and to other parasitized erythrocytes – 
agglutination8. The process of cytoadherence, rosetteing and 
 15
agglutination are central to pathogenesis of falciparum malaria. They 
result in sequestration of RBCs in vital organs where they interfere with 
microcirculatory flow and metabolism.10,11  
CLINCAL FEATURES 
The first symptoms of malaria are nonspecific: the lack of a sense 
of well – being, headache, fatigue, abdominal discomfort, and muscle 
aches followed by fever. The classical malarial paroxysms, in which 
fever spikes, chills, and rigor occur at regular intervals are relatively 
unusual in falciparum and suggest infection with P.vivax.9 The fever of 
falciparum malaria is irregular at first and the temperature often rises 
above 400 c in conjunction with tachycardia and sometimes delirium.  
 
FIG.2 
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Falciparum malaria presents with protean manifestations and is 
associated with a variety of complications and has a high mortality. 
Plasmodium falciparum in contrast to the benign malarias, may 
progress to a life threatening multisystem disease. Importantly the 
affection of renal, haematological, central nervous system adds to the 
mortality. Pernicious syndrome consisting of anemia, hypotension, 
haematological parameters and cerebral involvement is seen most 
commonly in plasmodium falciparum infection.  
Sometimes falciparum malaria presents with atypical 
presentations as evidenced by some of the studies. 
Falciparum malaria presenting as a leukaemoid reaction.12 
 In falciparum malaria clinical presentations were dominated by 
features other fever or the history of fever was totally absent. Some of 
the presentations were Acute abdomen, urticaria, and unexplained 
shock. 13 
According to WHO the term severe malaria is defined as the 
presence of one or more complication in a patient having asexual 
parasitemia in the peripheral blood smear.2  
COMPLICATIONS OF FALCIPARUM MALARIA 
MALARIAL HEMATOPATHY 
Malarial Hematopathy attempts to describe the involvement of 
one or more hematopoietic cell lines and includes the endothelial 
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dysfunction that can give rise to a thrombotic microangiopathy that may 
evolve into a consumptive coagulopathy. 
ANEMIA 
The pathogenesis of anemia in malaria is multifactorial. Anemia 
results from accelerated RBC destruction and removal by the spleen in 
conjunction with ineffective erythropoiesis. In severe malaria, both 
infected and uninfected RBCs show reduced deformability, which 
correlates with prognosis and development of anemia9. Splenic 
clearance of RBCs is increased.The cause of dyserythropoiesis is 
believed to be related to intramedullary cytokine production8. Anemia is 
a common consequence of antimalarial drug resistance, which results in 
repeated or continued infection9,14. 
THROMBOCYTOPENIA 
Thrombocytopenia is a common occurrence in acute malaria. It 
has been identified as a key indicator for malaria in patients with acute 
febrile illnesses. Thrombocytopenia is rarely accompanied by clinical 
bleeding or biochemical evidence of DIC. Platelet counts rapidly rise 
with recovery. 
The mechanism of thrombocytopenia in malaria is uncertain. 
Immune – mediated lysis, sequestration in the spleen and a dyspoietic 
process in the marrow with diminished platelet production have all been 
postulated. Abnormalities in platelet structure and function have been 
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described as a consequence of malaria, and in rare instances platelets 
can be invaded by malarial parasites themselves. 
Thrombopoietin (TPO) is the key growth factor for platelet 
production and is elevated in states of platelet depletion. TPO serum 
levels have been shown to be significantly higher in subjects with 
severe malaria, normalizing within 14 – 21 days of therapy.15     
Two types of changes in platelet dysfunction are seen in malaria. 
Initially there is platelet hyperactivity; this is followed by platelet 
hypoactivity. Platelet hyperactivity results from various aggregating 
agents like immune complexes, surface contact of platelet membrane to 
malarial red cells and damage to endothelial cells. The injured platelets 
undergo lysis intravascularly. The release of platelet contents can 
activate the coagulation cascade and contributes to DIC. Transient 
platelet hypoactivity is seen following this phase and returns to normal 
in 1 to 2 weeks.15. 
LEUCOCYTE COUNT 
Total leukocyte count is usually normal however leukocytosis can 
occur especially when associated with pernicious malaria and 
superadded bacterial infections. Leucopenia has also been observed.16 
Increase in the number of atypical lymphocytes has been reported in 
acute falciparum infection at times leading to false positive serological 
tests like the widal titres.17. 
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LIVER DYSFUNCTION 
Mild hemolytic jaundice is common in malaria. Severe jaundice is 
associated P.falciparum infections, is more common among adults than 
among children, and results from hemolysis, hepatocyte injury, and 
cholestasis. When accompanied by other vital organ dysfunction ( often 
renal impairment ), liver dysfunction carries a poor prognosis.9 
Hepatic dysfunction contributes to hypoglycemia, lactic acidosis, 
and impaired drug metabolism.  
The cause of jaundice in a patient of plasmodium falciparum 
malaria is multifactorial and includes  
¾ Intravascular hemolysis due to destruction of parasitised and non 
parasitised red blood cells. 
¾ Malnutrition, shock, DIC leading to microangiopathic haemolysis 
Hepatocyte dysfunction, which may be because of alteration in 
vascular flow     through the organ as parasitised red blood cells adhere 
to endothelial cells blocking sinusoids and obstructing intrahepatic blood 
flow.There is evidence of focal hepatocyte necrosis, cholestasis, bile 
stasis, granuolomatous lesion or malarial nodules. The bile stasis is 
because of impairement of bilirubin transport due to endothelial 
blockage and disturbance of hepatocyte microvilli 18, 19. 
In acute falciparum malaria, the liver is enlarged and weighs upto 
2.5 kg. It is congested and pigmented and dark brown. The predominant 
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histopathological changes in malarial liver comprises of a 
reticuloendothelial response i.e., Kupffer cell hyperplasia, presence of 
malarial pigement and congestion along with minor effects on 
hepatocytes.20    
Additional changes in morphology include steatosis, 21 focal 
hepatocyte necrosis. Parasitised red blood cells are seen in Kupffer 
cells and endothelial cells. Characteristically rectangular, crystalline 
malarial pigment granules are seen in these cells. The hepatocyte 
contains lipofuschin and hemosiderin alongwith fat droplets deposition. 
The space of Disse becomes narrow with loss of microvilli of both the 
hepatocytes and the bile canaliculi. These last two features have been 
suggested as the important factors related to hepatic dysfunction and 
cholestasis. 18  
RENAL IMPAIRMENT 
Incidence of ARF in malaria all over the world has been reported 
as 0.57% to 60 %. In India, the incidence of malarial ARF has been 
reported to be 13 % in North India, 17.8 % in New Delhi and 17.2 % in 
orrisa.22  
Renal impairment is common among adults with severe 
falciparum malaraia but rare among children. The pathogenesis of renal 
failure is unclear but may be related to erythrocyte sequestration 
interfering with renal microcirculatory flow and metabolism. Clinically 
and pathologically, this syndrome manifests as acute tubular necrosis. 
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Acute renal failure may occur simultaneously with other vital organ 
dysfunction or may progress as other disease manifestations resolve.9      
Other non specific mechanisms may come into play including 
hypovolemia, release of catecholamines and subsequent activation of 
the rennin – angiotensin system, complement activation, and 
rhabdomyolysis.23   ATN is the main renal complication but latent forms 
of acute glomerulonephritis have also been documented.  
In survivors, urine flow resumes in a median of 4 days and serum 
creatinine levels return to normal in a mean of 17 days.9 Age, oliguria, 
central nervous system involvement and DIC emerged as bad 
prognostic factors in a simple univariate analysis.24, 25  
PULMONARY INVOLVEMENT 
The clinical manifestations of pulmonary involvement may start 
suddenly at any time during the course of malaria, even after 
disappearance of circulating parasites and after several days of 
antimalarial therapy. The mortality rate is > 80 %.9 Pulmonary edema is 
the most important pulmonary manifestation of malaria.26 It is a common 
feature of severe malaria.  
The pathogenesis of this variant of adult respiratory distress 
syndrome is unclear. Capillary endothelial cells, which control the flux of 
fluids to the interstitial space, appear to be the most involved structure. 
These cells are activated by cytokines, produced by lymphocytes and 
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macrophages during the immune response, and express receptors and 
molecules of adhesion, allowing for sequestration of parasitized 
erythrocytes and adherence of cells, which will produce locally 
inflammatory mediators.  The inflammatory reaction and lesion of 
endothelial cell that ensue together with hemodynamic alterations 
induced by capillary  blockade due to sequestrated parasitized 
erythrocytes cause alterations  of vascular permeability and transfer of 
liquid to interstitial space and alveoles. The mean central venous 
pressure when pulmonary edema was markedly lower in ARDS than in 
non – ARDS.  Supporting the argument that fluid imbalance is not 
essential for malaria induced lung injury .27  
ARDS in malaria can be aggravated by overly vigorous 
administration of intravenous fluid. 9    
ARDS are often associated with septic shock. In this situation, 
pneumonia and /or bacteremia should be suspected and empirically 
treated since they may contribute to a fatal outcome.28   
The other presenting symptoms pertaining to pulmonary 
manifestations in malaria include cough, disposal, expectoration, and 
chest pain29. 
CEREBRAL MALARIA 
Coma is a characteristic and ominous feature of falciparum 
malaria and is associated with mortality of 20 % despite treatment. 
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Lesser degrees of obtundation, delirium, and abnormal behaviour 
should also be taken very seriously. The onset may be gradual or 
sudden following a convulsion. Cerebral malaria manifests as diffuse 
symmetric encephalopathy; focal neurological signs are unusual.9   
Adults rarely suffer (i.e., in < 3 cases) suffer neurological sequale. 
Cytoadherence, malaria toxin and cytokine production have provided 
some evidence for both the mechanical and toxin – cytokine hypothesis 
to explain the pathophysiology of this condition.30 
HYPOGLYCEMIA 
Hypoglycemia is an important and common complication. It 
results from a failure of hepatic gluconeogenesis and an increase in the 
consumption of glucose by both host and to a lesser extent – the 
malarial parasite. 
LACTIC ACIDOSIS 
Lactic acidosis commonly coexists with hypoglycemia and is an 
important contributor to death from severe malaria. Lactic acidosis is 
caused by the combination of anaerobic glycolysis31 in tissues where 
sequestered parasites interfere with microcirculatory flow, hypovolemia, 
and lactate production by the parasite and a failure of hepatic and renal 
lactate clearance. The prognosis of severe lactic acidosis is very poor.   
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FEATURES INDICATING A POOR PROGNOSIS IN SEVERE 
FALCIPARUM MALARIA9 
CLINICAL 
1. Marked agitation 
2. Hyperventilation 
3. Hypothermia (< 36.50 c) 
4. Bleeding  
5. Coma 
6. Repeated convulsions 
7. Anuria 
8. Shock 
LABORATORY 
BIOCHEMISTRY 
1. Hypoglycemia (< 40 mg/dl) 
2. Hyperlactatemia (>5 mmol/L) Acidosis (arterial pH <7.3, serum HCO3 
<15 mmol/L) 
3. Elevated serum bilirubin (>3 mg/dl) 
4. Elevated serum creatinine (>3 mg/dl) 
5. Elevated liver enzymes (AST/ALT 3 times upper limit of normal) 
6. Elevated muscle enzymes (CPK ↑ , myoglobin ↑) 
7. Elevated urate (> 600 µmol/L) 
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HEMATOLOGY AND COAGULOPATHY 
1) Leucocytosis (>12,000 /µL) 
2) Severe anemia(PCV<15%). 
3) Decreased platelet count (50,000/ul) 
4) Prolonged prothrombin time (>3s) 
5) Prolonged partial thromboplastin time 
6) Decreased Plasma Fibrinogen (100mg/dl) 
PARASITOLOGY 
1)  Hyperparasitemia  
Increased mortality at >100,000 / µL 
High mortality at >500,000 /µL 
20 % of parasites identified as pigment containing trophozoites 
and schizonts 
5 % of neutrophils with visible pigment  
MANAGEMENT OF SEVERE FALCIPARUM MALARIA: 32, 33 
IMMEDIATE MANAGEMENT 
Assess the Airway, Breathing, and Circulation and intervene 
when necessary. 
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Record the vital signs.  
Assess the level of consciousness using a coma scale – the 
Glasgow coma scale (GCS). 
Assess the state of hydration; consider catheterization of the 
urinary bladder and insertion of a line to measure central venous 
pressure. 
Treat hypoglycemia. 
Plan first 8 hours of intravenous fluids.  
Unconscious patients should have a lumbar puncture so that CNS 
infections, especially acute bacterial meningitis could be excluded with 
certainty. 
ANTI MALARIAL THERAPY FOR PL. FALCIPARUM 
Anti- Malarial 
(Parenteral) 
Loading dose Maintenance dose 
Cinchona Alkaloids   
Quinine 
dihydrochloride(IV) 
20 mg/kg over 4 hrs 10 mg/kg over 4 hrs 
Repeated every 8 hrs 
Artemisin derivatives   
Artesunate IV  2.4 mg/kg 1.2 mg/kg repeated at 
12 & 24 hrs, then 1.2 
mg/kg daily  
Artemether IM 3.2 mg/kg 1.6 mg/kg  repeated  
12-24 hrs, then daily 
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SUPPORTIVE THERPAIES 
FLUIDS 
The role of fluids in severe falciparum malaria is controversial. 
Hypovolemia is corrected by bolus of fluids that improve circulation.  In 
adults fluids must be used cautiously as they are at a greater risk of 
developing edema and circulatory overload. Fluid administration should 
be stopped and diuretics given if pulmonary edema is suspected. 
Monitoring the CVP is very helpful during administration of fluids. There 
is no evidence to show that fluid restriction improves the outcome in 
cerebral malaria. 
BLOOD TRANSFUSION 
Blood transfusion is life-saving in severe malarial anemia. The 
indication for blood transfusion depends on the availability of pathogen 
free compatible fresh blood, hemoglobin level and fluid balance status.34 
In a well–hydrated adult, a haematocrit value below 20% should be an 
indication for undertaking blood transfusion. 
ANTICONVULSANTS 
The management of seizures should include correction of the 
underlying cause, such as hypoglycemia. Anticonvulsants should be 
administered for seizures lasting for more than five minutes. 
Benzodiazepines are the most widely used and available 
anticonvulsants, but may cause respiratory depression. With repeated 
seizures phenytoin, phenobarbitone has been used. 
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HYPOGLYCEMIA 
Hypoglycemia is a common complication hence frequent 
checking of blood glucose level is mandatory. Correction with 50 % 
dextrose appears to be safe in adults. 
INOTROPIC SUPPORT 
Although shock (Algid malaria) is rare, it is associated with death. 
Inotropic support may be required after correction of hypovolemia. 
Dopamine appears to provide better inotropic support than adrenaline in 
adults with severe malaria. 
DIALYSIS 
The indications for dialysis in acute renal failure due to severe 
falciparum malaria are similar to the other causes of acute renal failure. 
Early diagnosis of established renal failure and institution of dialysis are 
important in preventing mortality. A rapidly rising creatinine level is the 
most sensitive indicator of the need for dialysis.   
VENTILATION 
Prompt endotracheal intubation by experienced personnel and 
mechanical ventilation may be a life saving procedure. Acute respiratory 
distress syndrome, poor respiratory effort, aspiration pneumonia, acute 
pulmonary edema and deep coma may benefit from ventilator support. 
Care must be taken to ensure frequent suction and adequate 
humidification during ventilation while maintaining a PaCO2 below 4.0 
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(KPa) since a rise in the PaCO2 may increase ICP and precipitate 
death. 
ANTIBIOTICS 
In patients with a reduced level of consciousness, the differential 
diagnosis of meningitis must be entertained and broad spectrum anti-
microbial agents should be administered until the diagnosis can be 
excluded. Patients put on ventilator support should also be covered with 
prophylactic antibiotics. 
DRUG RESISTANCE IN MALARIA 
In much of the tropics, drug resistant P. falciparum is increasing in 
distribution, frequency, and intensity. There is a growing belief among 
malariologists that, to prevent resistance, falciparum malaria should be 
treated with drug combinations and should no longer be treated with 
single drugs in endemic areas. 
The combination strategy is based upon simultaneous use of two 
or more drugs with different modes of action: one usually an artemisinin 
derivative (artesunate, artemether, or dihydroartemisinin), given for 3 
days and the other, a slower acting anti-malarial to which P.falciparum 
is sensitive9.  
When the malarial parasites are fully sensitive, either 
amodiaquine or sulfadoxine / pyrimethamine can be used in 
combination with the artemisinin derivative, or amodiaquine can be 
combined with sulfadoxine/ pyrimethamine. 
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MALARIA VACCINE DEVELOPMENTS 
Development of an effective and deployable malaria vaccine 
seems technically feasible in view of most malaria researchers. New 
vaccine delivery methods and adjuvants could continue to increase the 
antibody and cellular immunogenicity of subunit vaccination. The rate of 
clinical assessment of candidate malaria vaccines is increasing; in the 
past 5 years, the number of groups doing such research has increased 
from three to eleven35.  
A synthetic “cocktail” vaccine for P.falciparum, called SPf66 and 
developed by Dr.M. Patarroyo in Colombia7, has been tested 
extensively in South America and more recently in Africa and South 
East Asia. A recent field among children under age 5, in the United 
Republic of Tanzania showed the vaccine was safe, induced antibodies 
and reduced the risk of developing clinical malaria by about 30%., which 
confirmed the potential of vaccine to confer partial protection. As far as 
transmission blocking vaccines are concerned Pfs25 is a leading 
candidate7. 
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MATERIALS AND METHODS 
PLACE OF STUDY 
The study was carried out at Department of Medicine, Kilpauk 
Medical College Hospital, Kilpauk, Chennai –10. 
PERIOD OF STUDY 
Total period of study extended from June 2004to May 2005 
(12 Months). 
SAMPLE SIZE 
100 consecutive Acute Falciparum malaria patients admitted in 
medical wards and intensive care units in Department of Medicine, 
Kilpauk Medical College Hospital. 
TYPE OF STUDY 
The study carried out was an observational and prospective 
clinical study. 
MATERIALS AND METHODS 
One hundred cases of QBC MP positive falciparum malaria 
(confirmed by slide positivity for asexual stage of the parasite) admitted 
to the medical wards and intensive care units were included in the 
study. 
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EXCLUSION CRITERIA 
1. Patients below the age of 15 years. 
2. Pregnant and Lactating women. 
3. Patients – coexistence of both Falciparum malaria and 
Leptospirosis (MAST ≥  2 +) 
4. Mixed infections like associated plasmodium vivax. 
A detailed history and clinical examination was carried out to note 
complications and assess severity after obtaining written informed 
consent. 
The following laboratory investigations for hematological 
parameters were carried out: Hemoglobin estimation, Total and 
Differential Leucocyte count, Total Platelet count. In severe cases 
coagulation parameters like Bleeding time, whole blood   Clotting time, 
Prothrombin time were done. 
Biochemical investigations like blood Sugar, serum Bilirubin, 
Aspartate and Alanine aminotransferase, blood Urea, serum Creatinine 
and Electrolytes were also carried out. In patients with respiratory 
distress and renal failure X-ray Chest and Arterial Blood Gas Analysis 
were analyzed. HBsAg and Anti HCV in selected cases are done. 
All patients are treated with quinine and artemisin derivatives as 
the prevalence of Chloroquine resistant falciparum is very high in our 
area. 
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In severe falciparum malaria cases with multisystem involvement 
Leptospirosis and Dengue fever were ruled out by doing MSAT & MAT 
and IgM & IgG antibodies for dengue respectively. 
All patients were treated with antimalarials either Quinine or 
Artesunate depending upon clinical severity and tolerability of the 
patients. Other supportive measures in the form of antibiotics, 
anticonvulsants, antiemetics, blood transfusion inotropic support and 
fluids dialysis and ventilator support as and when required. 
ANALYSIS OF DATA 
All information pertaining to history, clinical examination, 
complications, relevant investigations, treatment modalities and duration 
of stay and also comparison of those data between mild and severe 
malaria were analyzed and tabulated. 
Hemoglobin <11g% has been taken as Anemia, Leucocyte 
counts <4000 and >11000cells/µl are taken as leucopenia and 
leucocytosis respectively, Platelet count <1,00,000 cells/µl as 
thrombocytopenia. Those with Serum Creatinine >1.5mg/dl were 
considered as acute renal failure and they were divided into three 
groups Mild (S.Cr.<2mg%), Moderate (S Cr.2 to 5mg%)and Severe 
(S.Cr.>5mg%). Serum bilirubin > 3 mg% SGPT/SGOT > 40 IU, as liver 
impairment. Hypoglycemia – Blood sugar <40mg%. 
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WHO CRITERIA FOR SEVERE FALCIPARUM MALARIA 
SYSTEMS INVOLVED                         MANIFESTATIONS 
Renal      Urine output (24 hrs) < 400 ml 
No improvement with rehydration 
Serum creatinine  >3 mg /dl. 
Respiratory     Respiratory distress.  
Pulmonary edema. 
ARDS (PaO2 /FiO2) :< 200 
ALI (PaO2 /FiO2) :< 300 
Cardiovascular    Hypotension / Shock 
Sys. BP. < 80 mm Hg. 
Neurological    Failure to localize or respond                       
Appropriately to noxious stimuli; 
Coma persisting for > 30 min 
after generalized convulsion. 
Hematological    Anemia  
Severe normocytic normochromic   
Hb < 5 gm/dl.  
Hct <15 %.   
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Liver      Jaundice 
Serum bilirubin > 3 mg/dl  
if combined with other evidence of  
vital organ dysfunction. 
Metabolic     Hypoglycemia  
Plasma  glucose < 40 mg/dl. 
Metabolic acidosis    Arterial PH   < 7.25  
Plasma  bicarbonate < 15 mmo/dl.  
LIMITATIONS OF THE STUDY     
The main limitation of the study is that we have not done the 
parasitemic index and hence could not assess its relation with clinical 
severity and laboratorial parameters and outcome of the disease.   
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OBSERVATION AND ANALYSIS 
PATIENT CHARACTERISTICS 
1.  SEX 
TABLE 1 
SEX N Mean SD Minimum Maximum
Male Age 59 35.7 12.9 15 63 
Female Age 41 40.0 15.7 15 72 
 
 A total of 100 cases smear positive for falciparum malaria were 
registered for the study. Out of 100 cases there were 59 males (59%), 
and 41 females (41%). The mean age in male was 35.7 years and 
female was 40.0 years.  
59%
41%
Male
Female
Distribution of Cases
 
FIG.3 
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2. AGE.  
TABLE 2 
N Valid 100 
  Missing 0 
Mean 37.48 
Std. Deviation 14.183 
Minimum 15 
Maximum 72 
 
The mean age of entire study group was 37.48, the minimum age 
being 15 years and the maximum age being 72 years. Maximum 
number of male patients was in the age group of 20 – 30 years (18%) 
and maximum number of female patients was in the age group of 30 – 
40 years (12%) as observed from figure 4.    
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CLINICAL MANIFESTATIONS 
The mean time from symptom onset until physician contact was 
7.3 days, while the median time was 5 days. The most common clinical 
presentation was fever (98%), followed by nausea and vomiting. 
Abdominal pain was present in sixteen patients. Nine patients had 
diarrhea. CNS manifestations were present in nine patients. Eight 
patients had urinary symptoms in the form of oliguria and anuria.  Three 
patients had bleeding manifestations.    
TABLE 3 
SYMPTOMS N % Of Patients 
Fever No 2 2.0% 
 Yes 98 98.0% 
Chills No 32 32.0% 
 Yes 68 68.0% 
Nausea No 70 70.0% 
 Yes 30 30.0% 
Vomiting No 50 50.0% 
 Yes 50 50.0% 
Headache No 72 72.0% 
 Yes 28 28.0% 
Myalgia No 63 63.0% 
 Yes 37 37.0% 
ABDOMINAL PAIN No 84 84.0% 
 Yes 16 16.0% 
DIARRHOEA No 91 91.0% 
 Yes 9 9.0% 
URINARY SYM No 92 92% 
 Yes 8 8% 
ALT. SENSORIUM No 91 91% 
 Yes 9 9% 
BLEEDING MANIF No 97 97.0% 
 Yes 3 3.0% 
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PHYSICAL SIGNS 
TEMPERATURE AT THE TIME OF PRESENTATION 
TABLE 4 
   TEMP. NO. of PTS 
<100o F 25 
100o F – 104o F 69 
>104o F 6 
 
Mean 100.9o F 
SD 2.04o F 
Min 97o F 
Max 105o F 
 
Fever was the most common presenting complaint. It was present 
in 98% of cases, but only 75% had a fever on the day of presentation. 
The mean temperature was 100.90 F and minimum being 97 and 
maximum being 105 F. The fever was associated with chills in 68% of 
cases.  
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SYSTOLIC BLOOD PRESSURE  
TABLE 5 
SYS. BP NO. of  PTS. 
<80 mm Hg 8 
81– 140 mm Hg 91 
>141 mm Hg 1 
 
     Mean     109.98 
SD         19.532 
Min         40 
Max         150 
 
Eight patients had hypotension at the time of admission.  
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TABLE 6 
SIGN  N % Of Patients 
Anaemic No 75 75.0% 
  Yes 25 25.0% 
Icterus No 73 73.0% 
  Yes 27 27.0% 
Hepatomegaly No 80 80.0% 
  Yes 20 20.0% 
Splenomegaly No 77 77.0% 
  Yes 23 23.0% 
Abd. tenderness         No        88               88.0% 
  Yes 12 12.0% 
Confusion & drowsiness No 91 91.0% 
  Yes 9 9.0% 
 
The most common clinical signs were icterus (27%), pallor (25%), 
splenomegaly (23%), hepatomegaly (20%), abdominal tenderness 
(12%) and CNS manifestations (9%). 
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HEMATOLOGICAL PARAMETERS IN FALCIPARUM MALARIA: 
TABLE  7 
PARAMETERS No of Cases MEAN SD MIN MAX 
Hemoglobin 
Less than 5 G% 
 
Nil 
5.1 – 7 G % 7 (7%) 
7.1  - 9 G 5 (5%) 
9.1 – 10.9 G % 27 (21%) 
≥ 11 G % 61 (61%) 
 
 
 
11.3 
 
 
 
2.3 
 
 
 
5.5 
 
 
 
16 
 
Leucocyte count 
cells/µl 
 
Less than 4,000 30 (30 %)
4,000 - 11,000 63 (63 %)
More than 11,000 7 (7%) 
 
 
5,687 
 
 
3,901 
 
 
1,700 
 
 
 
29,800 
Platelet count 
cells/µl 
 
Less than 20,000 10 (10%) 
20,000 - 50,000 29 (29%) 
51,000 - 1.00.000 39 (39%) 
More than 1,00,000 22 (22%) 
 
 
 
78,850 
 
 
 
62,983 
 
 
 
6,000 
 
 
 
 
3,61,000 
 
 
Thrombocytopenia (78%) and anemia (39%) were the most 
common hematological findings. Leucopenia was noted in 30% of 
cases, while 7 % of cases showed leucocytosis. 
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BIOCHEMISTRY IN PATENTS CLASSIFIED AS A, B, C GROUPS                          
ACCORDING TO SERUM BILIRUBIN LEVELS 
TABLE  8 
GROUPS A B C 
Serum bilirubin 
(mg%) <3 3 – 10 >10 
No. of patients 75  17  8  
Conjugated 48 12 8 
Unconjugated 27 5 - 
ALT level (IU)    
<40 65 1 - 
40 – 100 8 10 2 
> 100 2 6 6 
AST (IU)    
<40 64 2 - 
40 – 100 9 12 2 
> 100 2 3 6 
Mortality    
No. of patients 75 17 8 
Deaths - - 4 
Percentage - - 50% 
 
25 % of patients had serum bilirubin more than 3 mg%. 
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BIOCHEMICAL CHANGES - RENAL FUNCTION 
 TABLE  9 
BLOOD UREA  
Up to  40 mg % 63 (63%) 
       41 – 80 mg % 27 (27%) 
 More than 80 mg 
% 10 (10%) 
 
 
MEAN – 46.8 
SD – 59.1 
MIN-  10 
MAX -507 
 
TABLE  10 
SERUM CREATININE 
NORMAL (< 1.5 
mg%) 89 (89%) 
1.5 – 3 mg % 9 (9%) 
MORE THAN 3 mg 
% 2 (2 %) 
 
 
Mean --1.18 
SD – 1.5 
MIN. – 0.5 
MAX. – 15.2 
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TIME TAKEN -  RISE IN PLATELET COUNT ( 81 CASES) 
TABLE   11 
Days after Admn. % of Cases 
1 to 5 Days 48 
6 to 10 Days 31 
> 10 Days 2 
 
 
Mean      5.8 
SD           2.2 
Min         1 
Max         15 
 
TABLE   12 
TOTAL DURATION OF STAY 
NO OF DAYS NO  OF PATIENTS 
1 to 5 Days 45 
6  to10 Days 50 
> 10 Days 5 
Mean   6.32 
SD        2.28    
Min         1 
Max         15 
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DISCUSSION 
This study was a prospective clinical observational study done for 
a period of 12 months from June 2004to May 2005 Its objectives were 
to study the common clinical presentations and also atypical 
presentation if any of acute plasmodium falciparum malaria, to assess 
life threatening complications of severe malaria and to collect a detailed 
hematological and biochemical profile of acute falciparum malaria with 
objective of noting its abnormalities and correlation if any with clinical 
severity and prognosis. 
A total 100 cases of fever positive for malarial parasite by QBC 
method and confirmed for falciparum malaria by slide positive for 
asexual stage of Plasmodium faciparum who were admitted in medical 
wards and ICU ward at Department of Medicine, Kilpauk Medical 
College Hospital are taken. Our reference study which was conducted 
by Murthy GL. Sahay RK. Srinivasan VR. Upadhaya AC. Shantaram V. 
Gayatri K. (158 patients) was published in Journal of the Indian Medical 
Association Apr 2000.36. 
The mean age of presentation was 37.48 years (SD 14.18). In 
males the mean age was 35.7 years (SD12.9) and in females the mean 
age of presentation was 40.0 years (SD 15.7) which was similar to 
Murthy et al where it was 38.60 years (SD 15.45). Majority of cases 
were males 59% and 41% were females. In Murthy et al., it was also 
predominantly of male population (69.62%).  
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The commonest presenting manifestations were fever (98%), 
fever with chills and rigors (68%), followed by vomiting (50%), myalgia 
(37%), , headache (28%), and icterus (27%) The other less common 
manifestations are abdominal pain (16%), diarrhea (9%), altered 
sensorium (9%), urinary symptoms (8%). hypotension (8%) and 
bleeding manifestations (3%). 
The most frequently encountered complication is 
thrombocytopenia (78%) as against Murthy et al, in which it was 
(40.50%). In other studies  like UM Jadhav, et al., and Sharma SK et al, 
the incidence of thrombocytopenia were 78.4% and 90% of cases 
respectively which are very similar to our study and also highlights the 
fact that a persistent normal platelet count is unlikely in the laboratory 
findings of malaria.  
The thrombocytopenia was rarely accompanied by clinical 
bleeding or biochemical evidence of DIVC. Ten percent of patients had 
platelet counts below 25,000/µl. Platelet counts rise rapidly with 
recovery. Mean duration for recovery of platelet count was 5.8 days (SD 
2.2). Two patients took more than 10 days for recovery and the 
maximum duration was 15 days. Thrombocytopenia was seen in 40-90 
% of patients infected with P. falciparum infection in India. 
The incidence of anemia in our study is 39%, as against 74.68% 
in Murthy et al., and 86.7% cases in Sharma SK et al. The incidence of 
leucopenia was 30% which was higher than Sharma SK et al, which 
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had 6.7% and leucocytosis in our study was 7 % which was slightly 
lower than that of Sharma SK et al (13%). 
The incidence of acute renal failure in our study is 10% (Mild 
=3%, Moderate =6%, Severe=1%), as against 24.68% in Murthy et al. 
and similar to 4% of patients in Mehta KS et al. 40% of patients required 
dialysis in our study as against 92% in Mehta KS et al. Six patients had 
oliguria and 2 patients had anuria. Among patients with altered renal 
parameters mean urea on admission was 92.25 mg% (SD 88.58), 
maximum being 507 mg%. Maximum creatinine on admission was 15.2 
mg%. Two patients underwent hemodialysis.  
The incidence of malarial hepatopathy in our study is 25% where 
as it was 40.5% in Murthy et al. and 64% in DK. Kochar et al18. 17 % 
had bilirubin between 3 to 10mg/dl and 8 % had bilirubin more than 
10mg/dl and the maximum bilirubin was 29.5mg/dl which are similar to 
DK.Kochar et al.  According to WHO the patients of severe falciparum 
malaria with jaundice rarely have serum bilirubin levels of more than 
10mg%. Of the 8 cases of severe hyperbilirubinemia 4 cases died which 
may indicate a good prognostic marker. 
In our study we also observed raised serum liver enzyme levels in 
some of the patients. 75 % patients having bilirubin levels more than 
10mg% also had very high levels of serum enzymes which are similar to 
DK. Kochar et al. which had raised enzyme levels in 75 % patients with 
more than 10mg%. Earlier Chawla et al and Anand et al also had similar 
observations in patients of falciparum malaria. 
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In our study 2% patients developed ARDS and ALI in 1% patient 
which is similar to 4% patients in Rajput R et al29. All developing ARDS 
expired as in Rajput et al. Acute lung injury is more likely to occur in 
patients with extremely severe, multisystemic P. falciparum malaria. 
Prior antibiotic treatment does not change the incidence of ARDS due to 
falciparum malaria. 
In our study 9% of patients had cerebral malaria as against 
45.56% in Murthy et al. but was similar to 12.5% in Gopinathan VP .et 
al.37 Metabolic acidosis was present in 6% of patients. The degree of 
the metabolic acidosis in falciparum malaria correlates positively with 
disease severity. 
Out of the 6 patients presented with metabolic acidosis 5 patients 
had renal failure. The minimum PH   was 6.538 but it was seen in non 
renal failure case. The minimum PH in renal failure patients was 6.926.  
Out of 100 cases 8 % presented with hypotension, all the patients 
presented with multi system involvement. 4 patients died among them 
and 4 patients were managed with IV fluids and inotropic support. 
Among the 3 patients presented with bleeding manifestations one 
patient had normal bleeding time, coagulation time and prothrombin 
time with platelet count being 44,000 cells/dl. Another patient had 
multisystem involvement with increased prothrombin time and platelet 
count being 36,000 cells/dl.  
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In our study 1 patient presented with acute abdomen without 
fever and mimicked acute appendicitis. Another had pancytopenia 
without fever with a bleeding manifestation (epistaxis). 
The overall mortality in our study was 4% all of which were due to 
MODS (MULTI ORGAN DYSFUCTION SYNDROME). This coincides 
with    D.K.Kochar study, the leading cause of death in 2001 was MODS 
with predominant presentation of jaundice and renal failure.38      
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COMPARISON OF PROFILE WITH OTHER STUDIES 
Variables Our study 
(%) 
Murthy et al 
(%) 
Other studies (%) 
Fever 98 98.1 100(Nityan et al)39 
Fever,chills and 
rigors 
68 98.1  
Icterus 27 27.21 46.6(Nityan et al) 
Diarrhoea 9  10(Nityan et al) 
Algid malaria 8 18.35  
Renal failure 10 24.68 33.3(Habte et al) 40 
Cerebral malaria 9 45.56 12.5(Gopinathanetal) 
46.6(Nityan et al) 
Anemia 39 74.68 86.7(Sharma et al) 
78.3(Nityan et al) 
Thrombocytopenia 78 40.50 78.4(Jadhav et al) 
90(Sharma et al) 
Leucocytosis 7 - 13.3(Sharma et al) 
Leucopenia 30 - 6.7(Sharma et al) 
Bilirubin >10mg% 8 - 24 (Kochar et al) 
SGOT/SGPT>100I
U/L 
36 - 24 (Kochar et al) 
ARDS/ALI 3 - 15.1(Rajput et al) 
Bleeding Compl. 3 4.43  
Mortality 4 20.25 12(Kochar et al) 
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SUMMARY           
1) An observational  and prospective study was carried out from 
June 2004to  May 2005 at Department of Medicine, Kilpauk 
Medical College Hospital, Kilpauk, Chennai –10, with objectives 
of finding the common clinical presentation of Falciparum malaria 
and if any atypical presentation, hematological and biochemical 
parameters and their association  with disease severity and 
complications and prognostic indicators. 
2) 100 cases of fever, positive for malarial parasite by QBC method 
and confirmed for falciparum malaria by slide positive for asexual 
stage of P.falciparum were recruited into the study and followed. 
3) In our study males predominated accounting for 59% of cases 
and females were 41%. 
4) The mean age group in our study population was 37.48 years (SD 
14.18), maximum age being 72 years. Among male group the 
mean age was 35.7years (SD 12.9), maximum age being 63 
years. Most male patients’ age group was between 2nd and 3rd 
decade. In female group the mean age was 40.0 years (SD 15.7), 
the maximum being 72 years. Most female patients age group 
between 4th and 5th decade. 
5)  The mean time from symptom onset until physician contact was 
7.3 days while the median time was 5 days. 
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6) The most common clinical presentation was fever and it was 
present in 98% of cases. However it was associated with chills 
and rigor only in 68% of cases. 25% of patients were afebrile at 
the time of presentation. The fever does not follow a classic 
tertian pattern. The mean temperature was 100.9 F (SD 2.04) and 
the maximum being 105 F. 
7)  The next common presentation was vomiting (50%) followed by 
myalgia (37%), headache (28%), abdominal pain (16%) and 
diarrhea (9%).  9% had CNS manifestations and 8% had urinary 
symptoms. 
8) Among 2 patients (2%), without fever one had abdominal pain 
and vomiting mimicking acute appendicitis. Another patient had 
bleeding from nose. 
9) The commonest clinical sign apart from fever was icterus (27%) 
followed by pallor (25%). splenomegaly (23%) and hepatomegaly 
(20%)  
10) The most common hematological abnormality was 
thrombocytopenia (78%), with mean of 78,850/µl (SD 62,983), the 
minimum being 6000/µl  and the maximum being 3,61,000/µl. 
39% of cases had platelet count < 50,000/µl. Three patients had 
undergone platelet transfusion. 
11)  Anemia was present in 39 % of cases and mean Hb 11.3 g% (SD 
2.3), the minimum being 5.5 g%. Five  patients had undergone 
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blood transfusion for Hb less than 7 gm%.  Leucopenia (30%) and 
Leucocytosis (7%) were noted in our study. 
12) Liver impairment was noted in 25% of cases with bilirubin more 
than 3 mg%. 8% of patients had bilirubin more than 10mg%. The 
maximum bilirubin was 29.5mg%. Conjugated hyperbilirubinemia 
was noted in 20% of cases. ALT and AST were raised in 24% and 
23% cases respectively. Mortality was noted in cases with 
bilirubin more than 10 mg%. 
13) As per WHO criteria of sever falciparum malaria renal failure was 
noted only in 2% of cases with serum creatinine more than 3 
mg%.  One patient had creatinine 15.2 mg% and we could not 
dialyse as the patient had hypotension. Another patient had 
creatinine 3.3 mg% and was managed conservatively. 
14) Among patients with creatinine less than 3 mg%, we had 6% of 
patients with urea more than 100 mg% and 2 % patients had urea 
more than 80 mg%. In patients with urea more than 100 mg %, 
two patients had urea 180mg % and 176mg % with their 
creatinine being 2.5 mg % and 2.7 mg% respectively. Both had 
hypotension and were oliguric. After BP was stabilized with IV 
fluids and inotropic support they were taken up for dialysis, but 
could not be saved. 
15)  Eight (8%) had hypotension at the time of presentation.  
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16)  Six (6%) patients had metabolic acidosis. Among them 5 had 
liver impairment, 4 had hypotension, and 4 had renal involvement. 
Two of them undergone hemodialysis.  
17)  Nine (9%) patients had features of cerebral involvement . 
18)  2 % of patients developed ARDS and one patient developed ALI. 
Mortality was 100 % in ARDS group. 
19)  2 % patients had hypoglycemia which was managed with 50% 
dextrose. 
20)  Mortality rate was 4 % in our study group. All of them had 
hypotension metabolic acidosis, liver impairment and cerebral 
involvement. Renal impairment was noted among 3%. 2% of 
them had ARDS.  
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CONCLUSIONS 
1. The commonest clinical presentation is fever which is continuous 
and irregular but it has not followed a tertian pattern. 
2. The commonest hematological abnormality is thrombocytopenia 
followed by anemia. 
3.  Thrombocytopenia is rarely accompanied by clinical bleeding and 
has therapeutic implications in context of avoiding unnecessary 
Platelet infusions. 
4. Very severe anemia is not a common presenting feature in 
falciparum malaria in the study group. 
5. In our study the evidence of predominantly conjugated 
hyperbilirubinemia and increased levels of SGOT, SGPT levels 
suggest gross hepatocytic dysfunction in patients of Plasmodium 
falciparum malaria with jaundice. 
6. Patients developing ARDS has 100 % mortality.  
7. Factors associated with high mortality are renal failure, 
hypotension, metabolic acidosis, severe liver dysfunction, 
cerebral involvement and ARDS. 
8. In Chennai, Falciparum malaria should be included in the 
differential diagnosis whenever a patient is admitted for fever with 
MULTI ORGAN DYSFUNCTION. 
 61
PROFORMA 
 
Name:                                         Age:                         Sex: 
Registration no: 
Address: 
Date of admission: 
Date of discharge: 
Presenting complaints: 
Fever – duration                                
Chills and rigor 
Nausea and vomiting   
Myalgia and headache 
Diarrhea                                          
Abdominal pain  
Jaundice 
Oliguria / Anuria 
Altered sensorium 
Bleeding manifestations 
PHYSICAL EXAMINATION : 
Temp. At admn. : 
Pulse rate: 
Blood pressure:  
Respiratory rate: 
Anemia: 
Icterus: 
CVS: 
RS: 
Hepatomegaly: 
Splenomegaly: 
Abdominal tenderness: 
CNS exam. : 
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INVESTIGATIONS: 
Hematological: 
Hb %:                                                      PCV. : 
Leucocyte count:         Total:                  Differential: 
Platelet count:            At admn. :            At dis. : 
 
LIVER FUNCTION TESTS: 
 
Bilirubin:                   Total:                    Direct:                 Indirect: 
SGOT:                       SGPT: 
Total protein:             Albumin:              Globulin: 
 
RENAL FUNCTION TESTS: 
Blood Urea: 
Serum Creatinine: 
Urine Albumin:                 Sugar:                    Deposits: 
 
Blood sugar: 
SELECTIVE / SEVERE CASES: 
Coagulation: 
Bleeding time: 
Coagulation time: 
Prothrombin time: 
INR: 
Arterial Blood Gas analysis: 
X – Ray chest: 
ECG: 
Leptospirosis :  MAST :                            MAT : 
Dengue          :   IgM:                                IgG   : 
HBsAg:  Anti HCV: 
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